Bioxytran secures $1.6M stock purchase with Triton Funds; management forfeits $460K salaries

BIOXYTRAN, INC

Triton Funds LP commits up to $1.6M for up to 17.5M shares (19.9%) at lowest traded price 10 days prior to closing.
Proceeds: $805,000 to extinguish an existing note; balance for pre-clinical/clinical trials and working capital.
Management forfeits more than $460,000 in accrued salaries and expenses to support the transaction.
Closing requires effectiveness of a Form S-1 registration statement to be filed within 7 days; Triton gets $35,000 admin fee.
The deal follows Triton's prior investment; it aims to remove convertible note overhang and fund development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.